Background {#Sec1}
==========

Chronic hepatitis C (CHC) remains a major public health issue that might lead to cirrhosis and its complications, such as portal hypertension and hepatocellular carcinoma \[[@CR1]\]. Eradication of hepatitis C virus (HCV) has been associated with lower rates of liver-related complications \[[@CR2]\]. Transient elastography (TE) by FibroScan® (EchoSens, Paris, France) is a validated method to liver fibrosis assessment \[[@CR3]\] and seems to be cost-effective to diagnose cirrhosis compared to liver biopsy \[[@CR4]\]. The high efficacy of direct-acting antiviral drugs (DAAs) has revolutionized the management of patients with CHC. High rates of sustained virological response (SVR), defined as undetectable serum HCV-RNA levels 12 weeks after completing treatment, has been obtained by DAA treatment in patients with advanced liver fibrosis or compensate cirrhosis \[[@CR5]\]. However, the decrease of the burden of liver disease in CHC by DAA treatment might be associated with high costs to health authorities worldwide \[[@CR6]\]. Public health strategies should be implemented to promote primary care access to interferon-free regimes, especially in low to middle-income countries with high prevalence of CHC.

Drug prices are very important in HCV management but they are clearly not the only costs to be considered in the analysis \[[@CR7]\]. The decision to incorporate new drugs in guidelines for CHC management should take into account the cost and cost-effectiveness analysis. The evidence base from economic evaluations of new healthcare technologies has been limited by the quality of the available data, strengths and weaknesses of different methods used for cost determination and differences among public health systems worldwide \[[@CR8]\]. In Brazil, it is estimated that 1.4 to 1.7 million of people are living with CHC \[[@CR9]\], most of them genotype-1 (GT1) HCV \[[@CR10]\] and up to 20% with advanced fibrosis or cirrhosis \[[@CR11]\]. Recently, the Brazilian Ministry of Health (BMoH) has recommended the use of DAAs for CHC treatment due to high discounts given by pharmaceutical companies. Since July 2015, patients with advanced fibrosis (METAVIR F ≥ 3) have free access to these drugs \[[@CR12]\]. However, few studies have investigated the cost for CHC treatment with DAAs in a low to middle-income country. The aim of this study was to evaluate the guideline-based treatment costs by DAAs from the perspective of a public national reference healthcare institute in Brazil. In addition, we reviewed the literature for effectiveness of all-oral interferon-free regimens available in Brazil in real-life cohort studies.

Methods {#Sec2}
=======

Study design and setting {#Sec3}
------------------------

This cost-analysis study used cost data collected in a tertiary center for treatment of infectious diseases: National Institute of Infectious Diseases Evandro Chagas-Oswaldo Cruz Foundation (INI/FIOCRUZ) at Rio de Janeiro, Brazil. INI/FIOCRUZ has been playing an important role for the BMoH in development of public health policies and strategies for prevention and treatment of infectious diseases, including viral hepatitis. In the Brazilian Public Health System, known as *Sistema Único de Saúde* (SUS), individuals can have free access to HCV treatment whether confirmed presence of liver fibrosis. According to the recommendations for HCV treatment from the BMoH, treatment was delivery for free in patients with liver fibrosis stages F ≥ 2 until 2012. However, from 2013 to nowadays, the threshold for free-treatment access has changed for fibrosis stages F ≥ 3. This analysis simulated follow-up and antiviral regimens exclusively for treatment of GT1-HCV patients according to the recommendation of BMoH from 2011 to 2015.

Method for cost determination {#Sec4}
-----------------------------

The activity based costing (ABC) method was used for cost determination. This micro-costing method identifies different activities that the institution performs and includes the corresponding indirect costs (e.g. management costs) to estimate total cost of a procedure. ABC method recognizes the relationship between costs, activities (called cost drivers) and products (exams or medical visit) taking into account this relationship in the costing analysis \[[@CR13]\]. Secondary data were obtained from: (i) public access production resources from the Department of Statistics; (ii) inventory of permanent material; (iii) records of expenditures with resources from the Financial Department for a one-year (2013) period (to correct the potential seasonal expenses due to diseases outbreaks in infectious diseases); and (iv) cost of 450 diagnostic tests and 100 sub-types of clinical procedures. Administrative costs were estimated through the determination of the proportional contribution of each activity to the pooled expenses and considered for all diagnostic tests and clinical procedures. Prices in national currency \[Brazilian Real (BRL)\] and inflated to average prices of July of 2015 in United States Dollars according to the World Bank, without (exchange rate = 3.11) and with adjustment for purchasing power parity (PPP adjustment rate = 1.73). We report these as the "nominal price" (US\$) and the "PPP-adjusted price" (PPP\$), respectively.

Costs of personnel, blood analysis tests and medical visits {#Sec5}
-----------------------------------------------------------

Personnel costs for each procedure were calculated based on the annual salary payment of each employee and the working time spent in the specific activity. At INI/FIOCRUZ, salaries are determined according to employee's specialization (i.e., people with PhD degree have higher salaries compared to those without) for individuals working in similar activities. Regarding expenditures with blood analysis tests, we considered costs of materials needed to perform the test, such as kits and reagents. Methodology for cost determination of non-invasive methods for liver fibrosis assessment were detailed in the Supplementary Material. Briefly, the following aspects were taken into account to estimate the cost per unit of TE (i) the price and depreciation of the FibroScan® machine; (ii) annual maintenance by M probe calibration; (iii) salaries of personnel who perform the examination and (iv) indirect administrative costs. We reported the price of TE adjusted with the opportunity cost of using public resources for implementation of new technologies (cost of capital). Costs with specific material for liver biopsy \[Menghini needle 16G (Biomedical, Florence, Italy)\] and histological analysis, as well as personnel costs and cost for a day-clinic hospitalization were considered for estimation of total cost to perform a liver biopsy. The market prices were considered for diagnostic tests not performed at INI/FIOCRUZ.

Cost of antiviral drugs for CHC treatment {#Sec6}
-----------------------------------------

Drug costs were collected in a web-based public domain site that describes the prices paid by the BMoH for all drugs incorporated in the Public Health System and purchased from the pharmaceutical industry (Database of Health Prices -- "*Banco de Preços em Saúde*" - accessible at: <http://www.saude.gov.br/bps>). A weighted-mean price for each antiviral drug was estimated taking into account all drug payments made by the BMoH from January to December 2015. We then calculated the price for a single-dose of PEG-interferon α-2a 180 mcg (PEG-IFN) \[Pegasys® - Roche\] and a single capsule or tablet for ribavirin (RBV) \[generic by BMoH\], boceprevir (BOC) \[Victrelis® -- Merk\], telaprevir (TEL) \[Incivek® - Vertex Pharmaceuticals\], sofosbuvir (SOF) \[Sovaldi® -- Gilead\], daclastavir (DCV) \[Daklinza® - Bristol-Myers Squibb\] and simeprevir (SIM) Olysio® -- Janssen Pharmaceuticals\].

Strategies for treatment of GT1-HCV patients according to the BMoH guidelines {#Sec7}
-----------------------------------------------------------------------------

In the present study, we compared the strategies for HCV treatment of GT1 patients as recommended by the BMoH from 2011 to 2015. During this period, Brazilian guidelines for CHC treatment were published in 2011, 2013 and 2015. In 2011, GT1 patients should be treated by PEG-IFN plus RBV for 48 weeks and a liver biopsy with significant fibrosis (METAVIR F ≥ 2) was necessary for treatment access (regimen BMoH-2011) \[[@CR14]\]. In 2013, presence of advanced fibrosis (liver biopsy METAVIR F ≥ 3 or TE ≥ 9.6 kPa) allowed the addition of first generation protease inhibitors \[BOC for 44 weeks (regimen BMoH-2013A) or TEL for 12 weeks (regimen BMoH-2013B)\] to PEG-IFN/RBV during 48 weeks \[[@CR15]\]. More recently, in 2015, all-oral and interferon-free regimens \[SOF plus DCV for 12 weeks (regimen BMoH-2015A) or SOF plus SIM for 12 weeks (regimen BMoH-2015B)\] were recommended for GT1 HCV patients. Patients with decompensated cirrhosis, HIV co-infection or previous failure with PEG-IFN/RBV ± BOC or TEL might be treated by SOF/DCV 24 weeks. In addition, serological biomarkers or TE could replace liver biopsy for free-access to DAA treatment \[[@CR12]\]. In all scenarios, liver fibrosis was staged for treatment access and patients were followed with blood tests and medical visits. Table [1](#Tab1){ref-type="table"} summarizes the strategies for treatment of GT1 HCV patients according to the BMoH guidelines from 2011 to 2015.Table 1Description of strategies for treatment of genotype 1 chronic hepatitis C according to the Brazilian Ministry of Health from 2011 to 2015GuidelineFibrosis stagingPrerequisite for treatmentDrugsDuration (weeks)DosesInterventionsBMoH-2011Liver biopsyMETAVIR F ≥ 2PEG-IFN α-2a 180 mcg\
\[Pegasys® - Roche\]481 injection weeklyPEG-RBV for 48 weeks. Medical visit at screening, baseline, W2, W4 and every 4 weeks for W4 to W48. Response-guided therapy or stopping rules based on HCV-RNA at W4, W12 and W24. SVR at W72RBV 250 mg\
\[BMoH generic\]485 capsules dailyBMoH-2013ATELSM ≥ 9.6 kPaPEG-IFN α-2a 180 mcg\
\[Pegasys® - Roche\]481 injection weeklyLeading-phase with PEG-RBV for 4 weeks and PEG-RBV/BOC for 44 weeks. Medical visit at screening, baseline, W2, W4, W5, W6 and W8, and every 4 weeks from W8 to W48. Response-guided therapy or stopping rules based on HCV-RNA on W4, W12 and W24. SVR at W72RBV 250 mg\
\[BMoHgeneric\]485 capsules dailyBOC 200 mg\
\[Victrelis® -- Merk\]4412 tablets dailyBMoH-2013BTELSM ≥ 9.6 kPaPEG-IFN α-2a 180 mcg\
\[Pegasys® - Roche\]481 injection weeklyPEG-RBV/TEL for 12 weeks and PEG-RBV for 36 weeks. Medical visit at at screening, baseline, W1, W2 and W4, then every 4 weeks from W4 to W48. Response-guided therapy or stopping rules based on HCV-RNA on W4, W12 and W24. SVR at W72RBV 250 mg\
\[BMoH generic\]485 capsules dailyTEL 375 mg\
\[Incivek ® - Vertex\]126 tablets dailyBMoH-2015ATE or\
APRI or\
FIB-4LSM ≥ 9.6 kPa or APRI ≥1.5 or\
FIB-4 ≥ 3.25SOF 400 mg\
\[Sovaldi® -- Gilead\]121 tablet dailySOF/DCV for 12 weeks. Medical visits at screening, baseline, W2, W4, W8 and W12. No response-guided therapy or stopping rules. SVR at W24DCV 60 mg\
\[Daklinza® - BMS\]121 tablet dailyBMoH-2015BTE or\
APRI or\
FIB-4LSM ≥ 9.6 kPa or APRI ≥1.5 or\
FIB-4 ≥ 3.25SOF 400 mg\
\[Sovaldi® -- Gilead\]121 tablet dailySOF/SIM for 12 weeks or 24 weeks in presence of decompensated cirrhosis (Child-Pugh B/C). Medical visits at screening, baseline, W2, W4, W8 and W12. No response-guided therapy or stopping rules. SVR at W24SIM 150 mg\
\[Olysio -- Janssen®\]121 tablet daily*APRI* aspartate-to-platelet index, *BMoH* Brazilian Ministry of Health, *BOC* boceprevir, *DCV* daclastavir, *FIB-4* fibrosis-4 score, *kPa* kilopascal, *LSM* liver stiffness measurement, *PEG-IFN* peginterferon, *RBV* ribavirin, *SIM* simeprevir, *SOF* sofosbuvir, *SVR* sustained-virologic response, *TE* transient elastography, *TEL* telaprevir

Literature review for efficacy of SOF/DCV and SOF/SIM regimens in real-life scenario {#Sec8}
------------------------------------------------------------------------------------

We systematically searched the references using the following predetermined inclusion criteria: cohort study that included GT1 HCV patients treated in real-life scenario by SOF/DCV or SOF/SIM ± RBV for 12 weeks. This search was performed in June 2017 at MEDLINE (PubMed) (1966--2017) using the following terms: \["sofosbuvir" OR "Sovaldi®" OR "GS-7977" OR "simeprevir" OR "Olysio®" OR"TMC-435" OR "daclastavir" OR "Daklinza®" OR "BMS-790052"\] AND \["hepatitis C"\] AND \["real-world" OR "real-life"\] (Additional file [1](#MOESM1){ref-type="media"}: Table S1).

Results {#Sec9}
=======

Costs for liver fibrosis assessment {#Sec10}
-----------------------------------

The estimated costs of TE with personnel, machine and administrative costs were PPP\$ 40.08, 29.80 and 24.78, respectively. The nominal and PPP-adjusted costs of a single TE exam were PPP\$ 95.32 (US\$ 53.32). The adjustment using the opportunity cost lead to an increase in up 50% of TE price (Additional file [1](#MOESM1){ref-type="media"}: Table S2). Costs of APRI and FIB-4 were estimated at PPP\$ 27.85 (US\$ 15.48) and PPP\$ 36.58 (US\$ 20.33), respectively. Total cost for liver biopsy was PPP\$ 834.41 (US\$ 482.32) including material to perform liver biopsy and histological analysis \[PPP\$ 80.75 (US\$ 46.68)\], personnel costs \[PPP\$ 301.47 (US\$ 174.26)\] and cost for day-clinic hospitalization \[PPP\$ 452.19 (US\$ 261.38)\].

Costs for GT1 HCV treatment {#Sec11}
---------------------------

The estimated price of GT1 HCV treatment drugs was an important source of variability in the total cost for HCV treatment. PEG-IFN α-2a 180 mcg cost PPP\$ 648.00 (US\$ 360.22) per weekly injection and RBV was the least expensive drug costing PPP\$ 106.05 (US\$ 58.80) per week. The regimen PEG-IFN (180 mcg SC weekly)/RBV (1250 mg PO daily if body weight ≥ 75 kg) cost PPP\$ 754.05 or US\$ 419.18 per week. Considering the first generation protease inhibitors (PI), TEL had a higher cost compared to BOC \[PPP\$ 87.01 (US\$ 48.37) vs PPP\$ 7.96 (US\$ 4.42) per tablet). The weekly costs for treatment by BOC (800 mg PO q8hr) and TEL (750 mg PO q8hr) were PPP\$ 668.64 and 3654.42, respectively. Thus, the weekly costs for PEG-IFN/first generation PI regimens ranges from PPP\$ 1422.69 (with BOC) and 4408.47 (with TEL). Considering the DAAs, the NS5A inhibitor DCV 60 mg and the second generation PI SIM 150 mg cost PPP\$ 388.78 (US\$ 206.09) and PPP\$ 541.24 (US\$ 300.86) per week, respectively. In addition, SOF 400 mg, a NS5B polymerase inhibitor, had a PPP-adjusted and a nominal cost of PPP\$ 1014.23 and US\$ 563.78 weekly, respectively. The regimens SOF (400 mg PO daily)/DCV (60 mg PO daily) and SOF (400 mg PO daily)/SIM (150 mg PO daily) cost PPP\$ 1403.01 and US\$ 1555.47 per week, respectively. Table [2](#Tab2){ref-type="table"} summarizes the nominal and PPP-adjusted costs per unit for tests, medical care and drugs used in GT1 HCV patient management.Table 2Cost per unit and number of procedures for monitoring and injections/tablets for treatment of genotype 1 chronic hepatitis C according to different regimens recommended by the BMoH from 2011 to 2015Cost per unitPEG-RBVPEG-RBV/BOCPEG-RBV/TELSOF/DCVSOF/SIMUS\$PPP\$nnnnnTransient elastography53.3595.32--1111Liver biopsy482.32834.411--------Blood analysis tests WBC. RBC and platelet10.6219.1115171666 Fasting glucose4.868.7566666 BUN/creatinine4.848.7015161566 ALT4.858.7315161566 AST4.868.7415161566 Alkaline phosphatases4.778.5866666 GGT4.838.6966666 Total bilirubin4.848.7166666 Albumin5.079.1266666 INR6.6812.026131466 HCV genotype156.33281.2211111 HCV-RNA87.05156.6087722 TSH26.2647.23666---- Beta-hCG45.5281.8844444Medical follow-up GP's medical visit54.5498.1111111 Specialist's medical visit62.92113.1914141455 Blood sample collection37.8368.0615151566 Nursing consultation31.8357.2655544Drugs PEG-IFN α-2a 180 mcg -- SC injection360.22648.00484848---- Ribavirin 250 mg -- PO capsule1.683.03168016801680---- Boceprevir 200 mg -- PO tablet4.427.96--3612------ Telaprevir 375 mg -- PO tablet48.3787.01----504---- Sofosbuvir 400 mg -- PO tablet80.54144.89------8484 Daclastavir 60 mg -- PO tablet30.8755.54------84-- Simeprevir 150 mg - PO tablet42.9877.32--------84Costs in United States Dollars (US\$) and with purchasing power parity (PPP\$) on July 2015. Drug costs estimated as the weighted-mean price (<http://www.saude.gov.br/bps>)*BOC* boceprevir, *DCV* daclastavir, *PEG-IFN* peginterferon, *RBV* ribavirin, *SIM* simeprevir, *SOF* sofosbuvir, *TEL* telaprevir, *WBC* white blood cell, *RBC* red blood cell, *BUN* blood urea nitrogen, *ALT* alanine aminotransferase, *AST* aspartate aminotransferase, *AP* alkaline phosphatases, *GGT* gamma-glutamyl transpeptidase, *INR* international normalized ratio, *TSH* thyroid-stimulating hormone, *hCG* human chorionic gonadotropin, *GP* general practicionerTreatment regimens according to BMoH guidelines: PEG-RBV 48w \[BMoH-2011\]; PEG-RBV (48w)/BOC 44w \[BMoH-2013A\]; PEG-RBV (48w)/TEL (12w) \[BMoH-2013B\]; SOF/DCV 12w \[BMoH-2015A\] and SOF/SIM 12w \[BMoH-2015B\]

According to the procedures recommended at the BMoH's guidelines, treatment with PEG-IFN/RBV/first generation PI \[BMoH-2013A and B\] was the most expensive approach. In those recommendations, patients were treated for 48 weeks by PEG-IFN/RBV and BOC for 44 weeks \[total of PPP\$ 71,196.03 (US\$ 39,578.23) per patient\] or TEL for 12 weeks \[total of PPP\$ 86,250.33 (US\$ 47,946.92) per patient\]. Treatments by new all-oral interferon-free regimens were the least expensive approach: the costs for SOF/DCV \[BMoH-2015A\] and SOF/SIM \[BMoH-2015B\] were PPP\$ 19,761.72 (US\$ 10,985.90) and PPP\$ 21,590.91 (US\$ 12,002.75), respectively (Table [3](#Tab3){ref-type="table"}). In the presence of decompensated cirrhosis (Child-Pugh B/C), the necessity to treat with SOF/DCV for 24 weeks leads to an 84% increase in total costs \[PPP\$ 36,597.71 (US\$ 20,345.04)\]. In all scenarios, the drug costs were responsible by approximatively 90% of total cost for treat patients with CHC. The cost with medical visits and blood analysis tests fell by up to 40% in treatment with DAAs \[guidelines BoMH-2015A/B\] compared to regimens that used PEG-IFN \[guidelines BMoH 2011 and 2013A/B\].Table 3Monitoring and drugs costs (US\$ and PPP-adjusted US\$) for treatment of genotype-1 patient with chronic hepatitis C according to different regimens recommended by the BMoH from 2011 to 2015PEG-RBVPEG-RBV/BOCPEG-RBV/TELSOF/DCVSOF/SIMUS\$PPP\$US\$PPP\$US\$PPP\$US\$PPP\$US\$PPP\$TE----53.3595.3253.3595.3253.3595.3253.3595.32Liver biopsy482.32834.41----------------Total482.32834.4153.3595.3253.3595.3253.3595.3253.3595.32Blood analysis tests WBC. RBC and platelet159.39286.72180.64324.95170.02305.8463.76114.6963.76114.69 Fasting glucose29.2052.5229.2052.5229.2052.5229.2052.5229.2052.52 BUN/creatinine72.58130.5677.41139.2672.58130.5629.0352.2229.0352.22 ALT72.78130.9277.63139.6572.78130.9229.1152.3729.1152.37 AST72.91131.1677.78139.9172.91131.1629.1752.4729.1752.47 AP28.6151.4628.6151.4628.6151.4628.6151.4628.6151.46 GGT28.9952.1528.9952.1528.9952.1528.9952.1528.9952.15 Total bilirubin29.0452.2429.0452.2429.0452.2429.0452.2429.0452.24 Albumin30.4454.7530.4454.7530.4454.7530.4454.7530.4454.75 INR40.1072.1486.89156.3093.57168.3240.1072.1440.1072.14 HCV genotype156.33281.22156.33281.22156.33281.22156.33281.22156.33281.22 HCV-RNA696.431252.80609.381096.20609.381096.20174.11313.20174.11313.20 TSH157.55283.41157.55283.41157.55283.41---- Beta-hCG182.07327.53182.07327.53182.07327.53182.07327.53182.07327.53Total1756.413159.581751.943151.541733.453118.27849.941528.95849.941528.95Medical follow-up GP's medical visit54.5498.1154.5498.1154.5498.1154.5498.1154.5498.11 Specialist's visit880.951584.73880.951584.73880.951584.73314.62565.97314.62565.97 Blood sample567.521020.90567.521020.90567.521020.90227.01408.36227.01408.36 Nursing consultation159.15286.29159.15286.29159.15286.29127.32229.03127.32229.03Total1662.152990.021662.152990.021662.152990.02723.491301.47723.491301.47Drugs PEG-IFN 180 mcg17,290.5931,103.7817,290.5931,103.7817,290.5931,103.78-------- Ribavirin 250 mg2828.695088.492828.695088.492828.695088.49-------- Boceprevir 200 mg----15,991.5128,766.88------------ Telaprevir 375 mg--------24,378.6943,854.45-------- Sofosbuvir 400 mg------------6765.6812,170.686765.6812,170.68 Daclastavir 60 mg------------2593.444665.30---- Simeprevir 150 mg----------------3610.296494.49Total20,119.2836,192.2736,110.7964,959.1544,497.9780,046.729359.1216,835.9810,375.9718,665.17TOTAL COST24,020.1643,176.2839,578.2371,196.0347,946.9286,250.3310,985.9019,761.7212,002.7521,590.91Costs in United States Dollars (US\$) and with purchasing power parity (PPP\$) on July 2015. Drug costs estimated as the weighted-mean price (<http://www.saude.gov.br/bps>)*PEG-IFN* peginterferon, *WBC* white blood cell, *RBC* red blood cell, *BUN* blood urea nitrogen, *ALT* alanine aminotransferase, *AST* aspartate aminotransferase, *AP* alkaline phosphatases, *GGT* gamma-glutamyl transpeptidase, *INR* international normalized ratio, *TSH* thyroid-stimulating hormone, *hCG* human chorionic gonadotropin, *GP* general practicionerTreatment regimens according to BMoH guidelines: PEG-RBV 48w \[BMoH-2011\]; PEG-RBV (48w)/BOC 44w \[BMoH-2013A\]; PEG-RBV (48w)/TEL (12w) \[BMoH-2013B\]; SOF/DCV 12w \[BMoH-2015A\] and SOF/SIM 12w \[BMoH-2015B\]

Literature overview for efficacy of SOF/DCV and SOF/SIM regimens {#Sec12}
----------------------------------------------------------------

Out of 150 identified articles, 25 references were eligible and 14 real-life cohort studies that reported the efficacy of SOF/DCV (*n* = 2) or SOF/SIM ± RBV (*n* = 12) in GT1 HCV patients were included (Fig. [1](#Fig1){ref-type="fig"}). Overall, SVR rates for SOF/DCV ± RBV and SOF/SIM ± RBV during 12 weeks ranged from 83 to 98% \[[@CR16], [@CR17]\] and from 75 to 96% \[[@CR18]--[@CR29]\], respectively. SVR rates were lower in presence of cirrhosis compared to non-cirrhotic patients (87% vs 98% with SOF/DCV \[[@CR17]\] and 81% vs 91% with SOF/SIM \[[@CR26]\]. Higher SVR rates can be achieved in cirrhotic patients when extending SOF/DCV for 24 weeks \[[@CR17]\] or adding RBV to SIM/SOF \[[@CR24]\]. Pol et al. reported lower SVR rates in GT1a patients compared to GT1b (89% vs 95% with SOF/DCV 12 weeks) that might be not significant when extending treatment for 24 weeks (95% for both) \[[@CR17]\]. Similar results were observed in patients treated by SOF/SIM 12 weeks (83% for GT1a vs 90% for GT1b) \[[@CR26]\]. Table [4](#Tab4){ref-type="table"} summarizes SVR rates from real-life cohort studies that analysed the efficacy of SOF/DCV and SOF/SIM regimens in GT1 patients stratified by GT1 subtype and presence or absence of cirrhosis or previous treatment.Fig. 1Flow-chart of study selection for the literature overview Table 4Real-life cohort studies that evaluated efficacy (SVR12) of Sofosbuvir/Daclastavir (SOF/DCV) or Sofosbuvir/Simeprevir (SOF/SIM) regimens for treatment of HCV mono-infected genotype-1 patientsAuthorsYearLocalRegimenOverallNon-cirrhosisCirrhosisNaiveExperimentedGT 1aGT 1bnSVRnSVRnSVRnSVRnSVRnSVRnSVRSofosbuvir (400 mg)/Daclastavir (60 mg) regimen studies Pol et al. \[[@CR17]\]2017FranceSOF/DCV 12w16092%6698%9487%6488%9695%7395%8389%SOF/DCV 24w43995%9797%34294%4885%39196%21095%20995% Welzel et al. \[[@CR16]\]2016EuropeSOF/DCV ± RBV 12w31998%----------------15199%15597%Sofosbuvir (400 mg)/Simeprevir (150 mg) regimen studies Marino et al. \[\[28\]2017SpainSOF/SIM ± RBV 12w83592%----83592%---------------- Ramos et al. \[[@CR29]\]2017SpainSOF/SIM 12w17993%------------------------ Chang et al. \[[@CR27]\]2017USASOF/SIM 12w2191%------------------------ Sulkowski et al. \[[@CR26]\]2016USASOF/SIM 12w63985%27291%36781%65------37183%18590% Lutchtman et al. \[[@CR25]\]2016USASOF/SIM 12w14882%4388%19378%6287%8678%9479%4293% Pellicelli et al. \[[@CR24]\]2016ItalySOF/SIM/RBV 12w27096%----27096%---------------- Roytman et al. \[[@CR23]\]2016USASOF/SIM 12w13889%4393%9587%7687%5592%-------- Thornton et al. \[[@CR22]\]2016USASOF/SIM 12w11489%------------------------ Jayasekera et al. \[[@CR19]\]2016USASOF/SIM 12w3586%1392%2282%786%2886%-------- Pillail et al. \[[@CR20]\]2016USASOF/SIM ± RBV 12w11384%2391%9082%5789%5679%-------- Barron et al. \[[@CR21]\]2016USASOF/SIM ± RBV 12w3583%------------------------ Backus et al. \[[@CR18]\]2015USASOF/SIM 12w113075%66481%46268%69978%43171%63273%36680%*DCV* daclastavir, *GT* genotype, *SIM* simeprevir, *SOF* sofosbuvir, *SVR* sustained virological response, *w* week

Discussion {#Sec13}
==========

The present study highlighted that GT1 HCV treatment by effective DAAs might be less expensive than interferon-based regimens in a low-to-middle income country, mainly due to price negotiation between health authorities and pharmaceutical companies and lower costs with monitoring in the all-oral interferon-free treatments.

The cost of TE was increased due to the very high interest rates used in Brazil \[[@CR30], [@CR31]\] and higher expenses with personnel at INI/FIOCRUZ. TE could be less costly in countries with lower opportunity cost of public funds and in those where nurses perform the exams. Liver fibrosis staging by TE seems to be cost-effective compared to liver biopsy and it was priced from US\$ 21 to US\$ 73 in the United Kingdom and up to US\$ 145 in the United States \[[@CR4]\].

HCV eradication has been associated with a financial burden, especially due to high DAAs costs which are extremely variable worldwide \[[@CR6]\]. An analysis of for a 12-week SOF course price (PPP-adjusted) in 30 countries described that Poland (PPP\$ 101,063.00), Turkey (PPP\$ 91,339) and United States (PPP\$ 64,680) were the top three ranking countries with the most expensive prices. On the other hand, India (PPP\$ 1861), Mongolia (PPP\$ 2604) and Egypt (PPP\$ 3117) were the countries with the least expensive price for SOF-therapy \[[@CR32]\]. In 36 clinical sites in USA, real-world costs for PEG-IFN/RBV/BOC 48 weeks, PEG-IFN/TEL 48 weeks and SOF/SIM 12 weeks were US\$ 57,960; US\$ 113,400; US\$ 180,600; respectively. In addition, the mean cost per SVR in all-oral interferon-free was higher in patients with advanced fibrosis (US\$ 167,467 for F3F4 vs 116,579 for F0F1F2) \[[@CR33]\]. However, both studies only included cost of HCV medications, not adjunctive medications, hospital costs, or projected medical costs. Data from Europe and Canada reported a total cost \[mean (95%CI)\] of €14,559 (13,323--15,836) per patient and €38,514 (35,244--41,892) per SVR for IFN-based regimens considering treatment, monitoring and complications \[[@CR34]\]. The price disparities among countries might be explained partly by the pharmaceutical price-setting policies used in different countries and negotiation between health authorities and pharmaceutical companies. Some countries set prices according to explicit cost-effectiveness thresholds based on gross domestic product (GDP) per capita resulting in high prices without consideration of budget impact \[[@CR35]\]. Therefore, DAA treatment costs are lower in Brazil compared to others countries mainly due to intense negotiation of BMoH with pharmaceutical companies resulting in more than 90% discount over international prices for SOF, DCV and SIM \[[@CR9]\].

In the present study, the reduced price for DAAs and shorten treatment duration might explain the lower total cost for HCV eradication with all-oral interferon-free compared to IFN-based regimens. Weekly prices for PEG-IFN (US\$ 360 or PPP\$ 648), BOC (US\$ 371 or PPP\$ 672) and TEL (US\$ 2030 or PPP\$ 3654) were relatively high and longer duration treatment with IFN-regimens led to higher costs with monitoring and medical visits (mean cost of PPP\$ 6133.15 for IFN-based vs PPP\$ 2830.42 for interferon-free regimens). In addition, adverse events are more frequent in IFN-based regimens than DAA treatment leading to higher costs. Previous studies reported that extra medical visits and drugs used for adverse events treatment, such as epoetin-α or filgrastim, lead to an increase in costs for treatment with IFN-based regimens with first generation PI (BOC/TEL) \[[@CR36]\]. Costs per SVR might have 2-fold increase for patients with thrombocytopenia compared to those with normal platelet count when treated by IFN-based regimens \[€50,907 (95% CI, 44,151--59,612) vs €26,105 (23,068--29,296)\] \[[@CR34]\].

Data from real-world cohort studies have been showing higher SVR rates by 12-week course of SOF/DCV (up to 92%) \[[@CR17]\] and SOF/SIM regimens (up to 85%) \[[@CR26]\] compared to IFN-based regimens (up to 40% in cirrhotic patients treated by PEG-IFN/RBV/BOC or TEL) \[[@CR37]\]. However, presence of cirrhosis and GT subtype 1a might lead to lower SVR rates (Table [4](#Tab4){ref-type="table"}). The extension of SOF/DCV for 24 weeks might be used to achieve higher SVR rates in cirrhotic patients \[[@CR17]\]. In GT1 HCV infected patients, treatment using DAAs has been considered as cost-effective \[[@CR38]\] and further analysis are needed to evaluate whether this approach is cost-saving \[[@CR39]\]. In addition, treatment by SOF/DCV or SOF/SIM result in less medical visits and blood analysis tests for monitoring, lower rates of adverse events, no need of subcutaneous injection and lower intake of tablets/day compared to IFN-regimens. However, presence of decompensated cirrhosis highly increase the cost of treatment \[from PPP\$ 19,761.72to 36, 597.71 (from US\$ 10,985.9 to 20,345.04\] due to extension of SOF/DCV regimen for 24 weeks. Despite, the lack of cost-effectiveness studies in Brazil, given the fact that DAA-regimens are more effective compared to IFN-regimens and total cost for HCV treatment with all-oral interferon-free drugs is lower than IFN-based regimens, we could hypothesize that treatment with DAAs might be dominant in this country. Considering local costs and SVR rates reported in international real-life cohorts, the cost per SVR in Brazil could range from 20 to 30 thousand PPP\$. Early viral kinetics might be used to individualize duration of DAA therapy decreasing costs by up to 20% \[[@CR40]\]. On the other hand, treatment of patients with advanced fibrosis/compensated cirrhosis for 12 weeks, as recommended by the BMoH guideline, might lead to relative high rates of DAA failure or resistance and increased future costs for re-treatment. The addition of RBV (1250 mg PO daily) to SOF/SIM or SOF/DCV does not highly increase the cost of treatment due to local generic production and low price (US\$ 706 or PPP\$ 1273 per patient per 12 week duration). In Brazil, the prevalence of GT 1b seems to slightly higher than 1a (55% vs 45%) \[[@CR41]\]. Considering our HCV prevalence and costs described in the present study, the financial burden could be up to PPP\$ 21 billion (or US\$ 12 billion) to treat all GT1 HCV infected people independently of fibrosis stage in Brazil. This amount represents approximately 13% of the general government expenditure on health in Brazil during 2014 \[Health expenditure series. World Health Organization, available at: <http://apps.who.int/nha/database/Select/Indicators/en>; accessed at March 2017\].

The main limitations of the present study are the lack of primary data on patient's follow-up and costs of treatment for non-GT1 patients and new generation of interferon-free regimens. Presence of adverse events might lead to increased costs for medical care and low treatment adherence might result in higher costs and higher costs per SVR than our estimates, due to non-response/relapse. However, primary data on DAA-treatment remain scarce in Brazil because the strategy from BMoH for universal access to SOF, DCV and SIM has been recently implemented. We estimated the costs of an ideal follow-up for standard treatment of GT1, the most prevalent genotype, HCV patients according to recent BMoH's recommendations. We are aware that treatment with fixed dose one-tablet daily of SOF/ledispavir (400/90 mg) or SOF/velpatasvir (400/100 mg) for 12 weeks has been recommended as first-line therapies for GT1 patients with or without cirrhosis \[[@CR42]\]. These patients can also be treated with the fixed-dose combination of ombitasvir (12.5 mg), paritaprevir (75 mg) and ritonavir (50 mg) in one single tablet and dasabuvir (250 mg) \[PTV/r/OMV + DSV regimen\] or the fixed dose combination of grazoprevir (100 mg) and elbasvir (50 mg) in a single tablet once-daily \[[@CR42]\]. However, these drug combinations are not currently available in Brazil for cost estimation. Another major limitation might be the fact that we evaluated the costs for HCV treatment in a short-term horizon and without prospective follow-up to evaluate whether DAAs treatment are cost-saving compared to PEG-IFN regimens.

The main strengths of this analysis are the PPP-adjustment for costs, the estimation of "real-price" for HCV-drugs and those related to monitoring/medical care accounting for the economic costs of public funds in medical investments. PPP adjustment is essential to allow comparison of prices of goods and services across countries. For high-income countries, PPP adjustment results in lower prices. In contrast, countries with weaker purchasing power, such as Brazil, have a significant increase in prices with PPP adjustment \[[@CR43]\]. In the present study, the PPP-adjustment led to an increase in 1.8 fold in US\$ costs. The cost for each drug were defined as the weighted-mean price of all HCV-drugs bought by the BMoH in 2015 and registered in web-based and open-access platform. In addition, we analysed micro-costs of all procedures recommended pre, during and post-HCV treatment to allow the estimation of medical care financial burden beyond drug costs.

Conclusions {#Sec14}
===========

In conclusion, therapies with all-oral interferon-free, such as SOF/DCV and SOF/SIM for 12 weeks, have a high efficacy and need shorter treatment duration leading to lower costs for monitoring and medical care compared to IFN-based regimens in Brazil where DAAs had more than 90% discount over international prices. HCV treatment by IFN-free regimens will probably be associated with high financial impact worldwide. However, reduced DAA prices due to negotiation between health authorities and pharmaceutical companies can turn HCV treatment into an accessible strategy to HCV eradication.
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Additional file 1:Micro-costing analysis of guideline-based treatment by direct-acting agents: the real-life case of hepatitis C management in Brazil. (DOCX 28 kb)
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